PE Tech Report


Like this article?

Sign up to our free newsletter

Thabor Therapeutics secures €2m financing from Bpifrance

Thabor Therapeutics, a company developing a treatment for patients living with chronic mucosal inflammatory diseases, has secured €2 million ($2.09m) in funding from the French public investment bank Bpifrance, as part of its Deeptech Plan.

This funding will enable Thabor to accelerate its R&D programs and to build upon the very encouraging results achieved since the company was founded in June 2021; for the industrial development of its monoclonal antibodies and an IND (Investigational New Drug) application.
The funding from Bpifrance is another step towards the series A round planned for Q4, 2022. Thabor also intends to use the money for further staff recruitment to strengthen its team.

Like this article? Sign up to our free newsletter




Blackstone Private Equity